“Since the discovery of the JAK2 mutation in 2005, there has been tremendous excitement about the development of selective JAK2 inhibitors as a new treatment for MPNs. After six years of waiting, several drugs are in advanced clinical trials and one may soon be available for patients. Given these new drugs and other lines of clinical investigation, there are many reasons to be optimistic about the prospects for a cure.” - John Crispino, PhD, Northwestern Memorial Hospital, Scientific Advisor for MPN Research Foundation

If you are a company or investigator who is running a trial and you need to make a change to the listing for your trial contact our office at 312-683-7243 or by sending an email.

Additional sources:

The National Institutes of Health (NIH) provides information about clinical trials at www.clinicaltrials.gov. Since the database is a repository of trials for all diseases, we recommend you obtain MPN-specific trial information by typing the specific disease (eg. polycythemia vera) in the Search Clinical Trials box.

The National Cancer Institute (NCI) provides information on clinical trials for all cancers from around the world at www.cancer.gov/clinicaltrials/search. We recommend you obtain MPN-specific trial information by selecting “myeloproliferative disorders” in the Type of Cancer box. In the Subtype of Cancer box, select the specific MPN (e.g. essential thrombocythemia).
This information is provided to patients as a valuable resource and is not meant as an endorsement of any trials, institutions or physicians. Please consult your physician for advice before agreeing to join any trial.